About one in every 25 patients with chronic lymphocytic leukemia had abnormal liver function tests, and one in four developed liver dysfunction within 10 years, according to the results of a retrospective study.
The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for EGFR–positive non–small-cell lung cancer, according to a randomized phase III trial.
A large database study found that most patients with stage I endometrioid epithelial ovarian cancer or ovarian clear cell cancer do not have better survival outcomes when treated with adjuvant chemotherapy.
Women who take multivitamin supplements before their breast cancer diagnosis and during chemotherapy appear to be less likely to develop the debilitating, often long-lasting symptoms of chemotherapy-induced peripheral neuropathy, according to a new study.
The FDA has granted Priority Review status to pertuzumab (Perjeta) for the treatment of HER2-positive early breast cancer. The FDA will review the agent in combination with trastuzumab and chemotherapy, for use in the adjuvant setting.
Survival of patients with myelofibrosis who undergo splenectomy is adversely affected by older age, the need for transfusion, and leukocyte and circulating blast cell counts, according to a new analysis.
From 1989 to 2015, breast cancer death rates decreased by 39%, according to findings from a report from the American Cancer Society. This decrease translates to well over a quarter of a million averted breast cancer deaths in the United States.
In France and other countries with low to moderate incidence of melanoma, a new study has proposed recommending genetic testing using the rule of 3—screening those with 3 or more primary melanomas or genetically related cancers—instead of the rule of 2.
This video reviews 4-year quality-of-life results from a prospective, population-based study that looked at prostate cancer patients who selected either active surveillance, radical prostatectomy, or external-beam radiation.
This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.